IHMT-TRK-284

• Description:

  IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcr-Abl; c-Fms; c-Kit; PDGFR; Trk Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ihmt-trk-284.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=NC(C)=C(C2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3)S1)CN5CCN(C)CC5

• Molecular Formula:

  C25H27N7OS

• Molecular Weight:

  473.59

• References & Citations:

  [1]Beilei Wang, et al. Discovery of (E) -N- (4-methyl-5- (3- (2- (pyridin-2-yl) vinyl) -1H-indazol-6-yl) thiazol-2-yl) -2- (4-methylpiperazin-1-yl) acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. Eur J Med Chem. 2020 Dec 1;207:112744.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Abl; PDGFRα; PDGFRβ; TrkA; TrkB; TrkC

• CAS Number:

  [2416844-79-4]